On September 7, 2021 MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, reported that the company will participate in three upcoming investor conferences. Details of the company’s participation are as follows (Press release, DiaMedica, SEP 7, 2021, View Source [SID1234587415]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Conference: H.C. Wainwright 23rd Annual Global Investment Conference
Dates: September 13th – 15th, 2021
Format: One-on-one meetings, on-demand corporate presentation beginning September 13th at 7:00am ET
Conference: Lake Street Capital Best Ideas Growth (BIG5) Conference
Dates: September 14th – 15th, 2021
Format: One-on-one meetings
Conference: Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit
Dates: September 20th – 23rd, 2021
Format: One-on-one meetings
For more information or to schedule a one-on-one meeting with management, please contact your conference representative.